Sanofi Companies

 
Stock Quotes for Sanofi Companies top ^
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Large Core
  • Morningstar Rating: 4 Stars
Sign-up for sny investment picks
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Large Core
  • Morningstar Rating: 4 Stars
Sign-up for san investment picks
  • Industry: Drug Manufacturers - Major
  • Sector: Healthcare
  • Stock Style: Mid Growth
Sign-up for 500674 investment picks
  • Industry: Drug Manufacturers - Specialty & Generic
  • Sector: Healthcare
  • Stock Style: Large Core
  • Morningstar Rating: 4 Stars
Sign-up for sny investment picks

 
News Articles for Sanofi Companies top ^
Sanofi Group in Canada selects Partners In Research as national coordinator for the Sanofi BioGENEius Challenge Canada Canada NewsWire - National biotechnology research competition inspires teens to choose STEM careers - TORONTO , Sept.
Sign-up for Sanofi Group in Canada selects Partners In Research as national coordinator for the Sanofi BioGENEius Challenge Canada investment picks
2014/4/7
PARIS, April 7, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that following constructive discussions with the U.S. Food and Drug Administration (FDA) the company plans to resubmit in the second quarter its supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
Sign-up for Sanofi: Genzyme to Resubmit Lemtrada Application for FDA Review investment picks
- Treats Seasonal and Year-round Nasal Allergy Symptoms in Adults and Children - PARIS , July 31, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration's (FDA) Nonprescription Drugs Advisory Committee (NDAC) voted 10 to 6, with 2 abstentions, recommending approval of Nasacort ® AQ Nasal Spray (triamcinolone acetonide) for over-the-counter use in the U.S. (Logo:   http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) " Today's positive NDAC vote was an important step forward in providing broader access to Nasacort AQ for nasal allergy sufferers," said Charles Hugh-Jones , MD, MRCP, Chief Medical Officer, Sanofi US.
Sign-up for FDA Advisory Committee Recommends Approval of Sanofi's Nasacort® AQ Nasal Spray for Over-the-Counter Use investment picks
2014/2/27
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G012847-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/2/27/11G012847/SPLogoJpeg-575119179858.jpg http://www.marketwire.com/library/MwGo/2014/2/27/11G012847/Images/LSOReleaseImagejpeg-933772588927.jpg Paul Lucas, President and Chair of Life Sciences Ontario; Norm Kelly, Deputy Mayor of Toronto; Mark Lievonen, President and CEO of Sanofi Pasteur; Hon.
Sign-up for Mark Lievonen, President of Sanofi Pasteur Limited, Receives Lifetime Achievement Award From Life Sciences Ontario investment picks
Data Show Sanofi's Lyxumia® Added to Basal Insulin Lowered Blood Sugar Especially when Fasting Plasma Glucose was Controlled Canada NewsWire - Findings Consistent with Known Post-Prandial Effect of Lyxumia Supporting Combination with Basal Insulin - PARIS , Sept.
Sign-up for Data Show Sanofi's Lyxumia® Added to Basal Insulin Lowered Blood Sugar Especially when Fasting Plasma Glucose was Controlled investment picks
- Nasal Spray Treats Adults and Children with Seasonal and Year-Round Nasal Allergies - PARIS , Oct.
Sign-up for FDA Approves Sanofi's Nasacort® Allergy 24HR for Over-the-Counter Use investment picks
2013/12/5
New Data Support Flexibility in Timing of Administration for Sanofi's Lyxumia® Canada NewsWire - Similar glucose lowering effect when once-daily Lyxumia is administered before breakfast or the main meal - PARIS , Dec.
Sign-up for New Data Support Flexibility in Timing of Administration for Sanofi's Lyxumia® investment picks
2014/2/6
PARIS , Feb.
Sign-up for Sanofi Returns to Growth in Q4 2013 investment picks
Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide SWIFTWATER, Pa.
Sign-up for Sanofi Pasteur Initiates Phase III Study of Investigational Clostridium difficile Vaccine in the United States investment picks
Sanofi Pasteur Initiates Phase III Study of Investigational Vaccine in Canada to Prevent Clostridium difficile Canada NewsWire Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide TORONTO , Aug.
Sign-up for Sanofi Pasteur Initiates Phase III Study of Investigational Vaccine in Canada to Prevent Clostridium difficile investment picks
2013/9/9
Unilife grants Sanofi long-term exclusivity subject to Sanofi purchasing 150 million Unifill syringes per year following a four-year ramp-up Unilife to receive a minimum of $5 million and up to $15 million in milestone-based payments YORK, Pa.
Sign-up for Unilife Signs Long-Term Supply Contract with Sanofi for the Use of Unifill® Syringes with Lovenox® investment picks
- Efficacy trial in more than 30,000 older adults meets primary endpoint for superior efficacy - LYON, France , Aug.
Sign-up for Sanofi Pasteur's Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older investment picks
2013/9/24
- Findings Consistent with Known Post-Prandial Effect of Lyxumia Supporting Combination with Basal Insulin - PARIS , Sept.
Sign-up for Data Show Sanofi's Lyxumia® Added to Basal Insulin Lowered Blood Sugar Especially when Fasting Plasma Glucose was Controlled investment picks
- Similar glucose lowering effect when once-daily Lyxumia is administered before breakfast or the main meal - PARIS , Dec.
Sign-up for New Data Support Flexibility in Timing of Administration for Sanofi's Lyxumia® investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Sanofi Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Sandridge Energy  |  Next: SAP Business